Northeast Pharmaceutical Group Résultats passés
Passé contrôle des critères 1/6
Northeast Pharmaceutical Group has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.5% per year. Northeast Pharmaceutical Group's return on equity is 6.8%, and it has net margins of 4.3%.
Informations clés
35.5%
Taux de croissance des bénéfices
33.8%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 1.5% |
| Rendement des fonds propres | 6.8% |
| Marge nette | 4.3% |
| Dernière mise à jour des bénéfices | 30 Sep 2024 |
Mises à jour récentes des performances passées
Recent updates
Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture
Oct 30
It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)
Aug 07These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely
May 25Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Apr 05Ventilation des recettes et des dépenses
Comment Northeast Pharmaceutical Group gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Sep 24 | 7,973 | 347 | 2,056 | 108 |
| 30 Jun 24 | 7,905 | 380 | 2,066 | 108 |
| 31 Mar 24 | 7,829 | 346 | 2,270 | 101 |
| 31 Dec 23 | 8,243 | 358 | 2,573 | 97 |
| 30 Sep 23 | 8,643 | 442 | 2,839 | 146 |
| 30 Jun 23 | 8,895 | 373 | 3,031 | 146 |
| 31 Mar 23 | 8,810 | 352 | 2,913 | 152 |
| 01 Jan 23 | 8,809 | 350 | 2,789 | 160 |
| 30 Sep 22 | 8,609 | 202 | 2,727 | 106 |
| 30 Jun 22 | 8,555 | 151 | 2,752 | 102 |
| 31 Mar 22 | 8,478 | 129 | 2,776 | 93 |
| 31 Dec 21 | 8,145 | 99 | 2,711 | 83 |
| 30 Sep 21 | 8,003 | 37 | 2,613 | 62 |
| 30 Jun 21 | 7,671 | 14 | 2,530 | 61 |
| 31 Mar 21 | 7,465 | 71 | 2,458 | 69 |
| 31 Dec 20 | 7,384 | 12 | 2,453 | 74 |
| 30 Sep 20 | 7,659 | -1 | 2,751 | 76 |
| 30 Jun 20 | 7,833 | 113 | 2,784 | 74 |
| 31 Mar 20 | 8,026 | 97 | 2,901 | 73 |
| 31 Dec 19 | 8,220 | 174 | 3,014 | 64 |
| 30 Sep 19 | 7,898 | 214 | 2,880 | 137 |
| 30 Jun 19 | 7,828 | 198 | 2,823 | 154 |
| 31 Mar 19 | 7,622 | 200 | 2,724 | 148 |
| 31 Dec 18 | 7,467 | 195 | 2,581 | 145 |
| 30 Sep 18 | 7,102 | 196 | 2,443 | 73 |
| 30 Jun 18 | 6,659 | 196 | 2,214 | 72 |
| 31 Mar 18 | 6,204 | 160 | 1,987 | 62 |
| 31 Dec 17 | 5,676 | 119 | 1,740 | 58 |
| 30 Sep 17 | 5,271 | 98 | 1,470 | 26 |
| 30 Jun 17 | 5,176 | 60 | 1,416 | 0 |
| 31 Mar 17 | 5,016 | 39 | 1,318 | 0 |
| 31 Dec 16 | 4,814 | 24 | 1,236 | 0 |
| 30 Sep 16 | 4,581 | -156 | 1,204 | 0 |
| 30 Jun 16 | 4,122 | -295 | 1,204 | 0 |
| 31 Mar 16 | 4,031 | -358 | 1,223 | 0 |
| 31 Dec 15 | 3,834 | -384 | 1,153 | 0 |
| 30 Sep 15 | 4,006 | -194 | 1,078 | 0 |
| 30 Jun 15 | 4,092 | -77 | 1,009 | 0 |
| 31 Mar 15 | 4,223 | -8 | 1,039 | 0 |
| 31 Dec 14 | 4,333 | 87 | 1,077 | 0 |
| 30 Sep 14 | 4,260 | -27 | 1,224 | 0 |
| 30 Jun 14 | 4,199 | -56 | 1,226 | 0 |
| 31 Mar 14 | 4,022 | -77 | 1,178 | 0 |
| 31 Dec 13 | 3,871 | -167 | 1,130 | 0 |
Des revenus de qualité: 000597 has a large one-off gain of CN¥206.2M impacting its last 12 months of financial results to 30th September, 2024.
Augmentation de la marge bénéficiaire: 000597's current net profit margins (4.3%) are lower than last year (5.1%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 000597's earnings have grown significantly by 35.5% per year over the past 5 years.
Accélération de la croissance: 000597's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 000597 had negative earnings growth (-21.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Rendement des fonds propres
ROE élevé: 000597's Return on Equity (6.8%) is considered low.